在刚刚落幕的第61届美国临床肿瘤学会（ASCO）年会上，全球肿瘤治疗领域再次迎来振奋人心的消息。多项针对乳腺癌、肺癌和血液肿瘤的最新临床研究数据重磅发布，这些突破性进展不仅为患者带来了新的治疗选择，更彰显了医学界在抗击癌症道路上的坚定承诺。
乳腺癌治疗新突破：伊那利塞显著延长PIK3CA突变患者生存期
对于内分泌耐药、PIK3CA突变且HR+/HER2-的局部晚期或转移性乳腺癌患者而言，一线治疗方案的突破至关重要。III期INAVO120研究的最新数据显示，伊那利塞（inavolisib）联合哌柏西利（palbociclib）和氟维司群（fulvestrant）的治疗组合，将患者的中位总生存期（OS）延长至34个月，相较于安慰剂联合对照组的27个月，显著延长了7个月。这意味着携带PIK3CA突变的HR阳性、HER2阴性晚期乳腺癌患者的死亡风险降低了30%以上。
PIK3CA突变在HR阳性晚期乳腺癌中普遍存在，约占40%，且常预示着不良预后。除了INAVO120研究，伊那利塞（Itovebi™）目前还在多项III期临床试验（INAVO121, INAVO122, INAVO123）中进行评估，旨在探索其在不同联合治疗方案下，为更多PIK3CA突变乳腺癌患者带来靶向治疗的益处。这些研究的积极进展，为乳腺癌患者带来了新的希望，也为乳腺癌靶向药的研发指明了方向。
广泛期小细胞肺癌：阿替利珠单抗联合鲁比替康带来生存获益
小细胞肺癌（SCLC）是一种侵袭性极强、预后较差的肺癌类型，尤其是广泛期小细胞肺癌（ES-SCLC），治疗选择相对有限。III期IMforte研究的积极结果显示，阿替利珠单抗（Tecentriq）联合鲁比替康（Lurbinectedin）作为广泛期小细胞肺癌一线维持治疗方案，取得了显著的生存获益。该方案将疾病进展或死亡风险降低了46%，死亡风险降低了27%。
这是首个在广泛期小细胞肺癌一线维持治疗中，同时证实无进展生存期（PFS）和总生存期（OS）均取得临床意义改善的III期研究。这一突破性发现，为ES-SCLC患者提供了急需的有效治疗选择，也为肺癌治疗领域注入了新的活力。对于寻求抗癌药代购或了解仿制药信息的患者，关注此类最新临床研究进展至关重要。
复发或难治性淋巴瘤：格罗菲妥单抗方案展现巨大潜力
弥漫性大B细胞淋巴瘤（DLBCL）是一种侵袭性淋巴瘤，对于不适合移植的复发或难治性（R/R DLBCL）患者，有效的治疗方案尤为紧迫。III期STARGLO研究的两年随访更新数据证实，格罗菲妥单抗（Glofitamab）联合吉西他滨（Gemcitabine）和奥沙利铂（Oxaliplatin）的Glofit-GemOx方案，可显著延长患者的总生存期。目前中位OS尚未达到，疾病死亡风险降低了40%。
更令人鼓舞的是，在Glofit-GemOx方案治疗结束时获得完全缓解的患者中，82%未发生疾病进展，且完全缓解率高达58.5%，患者可持续获得完全缓解状态。作为一种亟需的、固定疗程、“即用型”TCE疗法，Glofit-GemOx方案在治疗侵袭性、危及生命的复发或初始治疗失败的DLBCL方面展现出巨大潜力，为淋巴瘤新药的研发和应用带来了新的曙光。
获取前沿抗癌药与专业支持：您的海外购药指南
这些在ASCO年会上公布的最新临床研究进展，无疑为癌症患者带来了更多希望。随着全球医疗科技的飞速发展，越来越多的创新靶向药和抗癌药问世，但患者在获取这些药物，特别是海外新药时，常面临诸多挑战，例如海外购药渠道、靶向药价格、以及如何获取专业的药物信息和诊疗指南。
如果您对这些创新靶向药、抗癌药的海外购药途径、仿制药信息或AI问诊服务感兴趣，可以访问MedFind官网获取更多详情，或通过海外靶向药代购服务了解具体购药流程。同时，AI问诊服务和丰富的药物信息与诊疗指南，将为您提供全面的抗癌支持，助您更好地了解和选择适合的治疗方案。
参考文献：
[1] Turner NC, et al. INAVO120 Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC). Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2025 May 30-June 03; Chicago, USA. Abstract #1003.
[2] Fillbrunn M, et al. PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22(1):1002.
[3] Anderson E, et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020:3759179.
[4] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) [Internet; cited 2025 May]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04191499.
[5] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) [Internet; cited 2025 May]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05646862.
[6] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122) [Internet; cited 2025 May]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05894239.
[7] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123) [Internet; cited 2025 May]. Available from: https://clinicaltrials.gov/study/NCT06790693.
[8] Paz-Ares L, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Presented at: ASCO Annual Meeting; 2025 May 30-Jun 03; Chicago, IL, USA. Abstract #8006.
[9] Belluomini L, et al. Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis. Seminars in Oncology. 2022; 49(5): 389-393.
[10] Roviello G, et al. No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials. Clin Lung Cancer. 2016; 17(5): 334–340.
[11] Paz-Ares L, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 02. [Internet; cited June 2025]. Available from: https://doi.org/10.1016/S0140-6736(25)01011-6.
[12] Abramson J, et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. Presented at: ASCO Annual Meeting; 2025 May 30 – Jun 3. Abstract #7015.
